Login to Your Account



Other News To Note


Monday, June 20, 2011
Sunshine Biopharma Inc., of Montreal, signed an agreement with the Jewish General Hospital to advance lead compound Adva-27a through preclinical development and Phase I trials. Adva-27a is a small-molecule Topoisomerase II inhibitor. Sunshine also has a similar agreement with the Research Foundation of the State University of New York, acting on behalf of Binghamton University, of Binghamton, N.Y.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription